RxDoctor Payments Data

Brock Harper, MD

Rheumatology · Cedar Park, TXNPI 1700968005

Payments from drug & device makers

$78,142in general payments, 2019–2025

Across 1,372 payments — averaging $56.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$44K
  • Novartis$5K
  • Lilly USA, LLC$5K
  • AbbVie$4K
  • Amgen$4K
  • UCB, Inc.$3K
  • plus $13K from 44 others

What the payments were for

  • Consulting fees$11,64815%
  • Speaking & faculty fees$31,06641%
  • Travel & lodging$5,1657%
  • Food & beverage$28,21837%
  • Education$2950%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,142 in reported general payments places this provider in the 80th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$1,455,674
Medicare patients
374
Services billed
107,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab56$684,870
RinvoqUpadacitinib47$487,581
Enbrel SureclickEtanercept17$216,756
Orencia ClickjectAbatacept27$187,342
KevzaraSarilumab24$178,871
Actemra ActpenTocilizumab19$137,200
Xeljanz XrTofacitinib Citrate22$125,004
Cosentyx Sensoready PenSecukinumab13$122,897
EnbrelEtanercept11$78,028
Hydroxychloroquine Sulfate220$8,920
MethotrexateMethotrexate Sodium156$6,529
Prednisone397$6,344
Cevimeline Hcl27$5,856
Celecoxib136$3,378
Leflunomide56$2,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$4,134$487,58147 claims
SanofiKevzara$1,127$178,87124 claims
AmgenEnbrel$3,666$78,02811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Cedar Park

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →